par Lefebvre, Pascal 
;Friart, Alain
Référence Revue médicale de Bruxelles, 20, 4, page (A245-A249)
Publication Publié, 1999
;Friart, Alain Référence Revue médicale de Bruxelles, 20, 4, page (A245-A249)
Publication Publié, 1999
Article révisé par les pairs
| Résumé : | Anticoagulants, including heparins and anti-vitamins K are medicines which are largely prescribed in cardiology. Even though the outlines of the treatment have been clearly established for a few decades, new cardiological indications have recently appeared. The long-term treatment of cardiac valvular prothesis by oral anticoagulants significantly reduces the risk of thrombo-embolic incident among people carrying a cardiac prothesis. In case of non-operated valvulopathy, treatment indication must be evaluated for each patient; in so doing, the connection benefit/risk must always be taken into account. In case of dilated cardiomyopathy, the treatment prescription must be limited to the patients with a high embolic risk. Other cardiological indications (apart from atrial fibrillation) must be carefully weighed up. |
